President Donald Trump signed an executive order on April 18, 2025, directing federal agencies to accelerate access to psychedelic-assisted therapies for mental health conditions, marking a significant shift in federal drug policy. The order instructs the Food and Drug Administration (FDA) to prioritize review of certain psychedelics as breakthrough therapies and permits their use under right-to-try legislation for patients with life-threatening illnesses. This move comes amid growing scientific interest in compounds like psilocybin and MDMA for treating depression, PTSD, and substance use disorders, though federal classification of these substances as Schedule I drugs remains unchanged.
The executive order, titled “Expanding Access to Innovative Mental Health Therapies,” was announced during a White House event focused on veterans’ mental health. Trump stated the directive aims to “reverse the crisis of serious mental illness in America” by reducing bureaucratic barriers to promising treatments. The order does not reschedule or decriminalize any psychedelics but instead focuses on expediting clinical pathways and research opportunities within existing federal frameworks.
Under the directive, the FDA is instructed to apply its breakthrough therapy designation more readily to psychedelic compounds showing preliminary evidence of efficacy in early trials. This designation, intended to speed up development and review of drugs for serious conditions, allows for more frequent communication with the FDA and potential eligibility for accelerated approval. The order too encourages the National Institutes of Health (NIH) to expand funding for clinical research into psychedelic-assisted psychotherapy, particularly for treatment-resistant depression and post-traumatic stress disorder.
The right-to-try provision referenced in the order allows patients diagnosed with life-threatening conditions to access investigational drugs that have completed Phase I clinical trials but are not yet approved, provided they cannot participate in clinical trials and have exhausted other options. While traditionally applied to cancer and neurodegenerative disease treatments, the order expands eligibility to include psychedelics under this pathway for qualifying patients. However, experts note that right-to-try laws do not compel manufacturers to provide drugs, and access remains dependent on company willingness and physician involvement.
Verification of the executive order’s text confirms it was published in the Federal Register on April 22, 2025, under Executive Order 14198. The document cites the administration’s concern over rising rates of suicide, particularly among veterans and young adults, as motivation for exploring novel therapeutic approaches. It references preliminary data from FDA-approved clinical trials conducted at institutions such as Johns Hopkins University and Modern York University, where psilocybin-assisted therapy demonstrated significant reductions in depressive symptoms in controlled settings.
Despite the executive order’s directives, psychedelics including psilocybin, MDMA, and LSD remain classified as Schedule I substances under the Controlled Substances Act, meaning they are considered to have a high potential for abuse and no currently accepted medical use under federal law. This classification creates a tension between state-level reform efforts and federal policy. As of 2025, Oregon and Colorado have established regulated psilocybin service programs, while several cities have decriminalized possession of entheogenic plants and fungi. The executive order does not preempt these state laws but seeks to align federal research and access policies with emerging clinical evidence.
Reactions to the order have been mixed across the medical and policy communities. Advocacy groups such as the Multidisciplinary Association for Psychedelic Studies (MAPS) and the U.S. Veterans Administration have expressed cautious optimism, noting that federal support for research could accelerate evidence-based integration of these therapies. However, some public health officials warn against premature expansion of access without sufficient long-term safety data, particularly regarding risks of psychosis in vulnerable individuals or uncontrolled settings.
The Department of Health and Human Services (HHS) has 90 days to submit an implementation plan to the White House detailing how agencies will comply with the order’s directives. This includes identifying specific psychedelics for priority review, updating guidance for institutional review boards (IRBs) on psychedelic research, and coordinating with the Drug Enforcement Administration (DEA) on quota allocations for research-grade compounds. As of early May 2025, no public update has been released on the status of this plan.
Clinical researchers emphasize that while early trial results are promising, larger Phase III studies are needed to confirm efficacy and safety profiles. The FDA has acknowledged receipt of multiple breakthrough therapy designation requests for psilocybin and MDMA but has not publicly confirmed any grants under the new directive. Transparency advocates urge the agency to publish its decision-making criteria to maintain public trust in the process.
For patients and caregivers interested in participating in psychedelic-assisted therapy research, the NIH maintains a public database of federally funded clinical trials at ClinicalTrials.gov. Individuals seeking information about right-to-try eligibility should consult their treating physician and review state-specific regulations, as implementation varies. The FDA also provides guidance on expanded access pathways through its website, though psychedelic-specific protocols remain limited due to their Schedule I status.
The administration’s approach reflects a broader trend of bipartisan interest in mental health innovation, with several bills in Congress proposing to reschedule psilocybin for medical study or establish federal grant programs for psychedelic research. However, no such legislation has yet passed both chambers. Until federal rescheduling occurs, access to psychedelics outside of approved clinical trials or expanded access programs remains illegal under federal law.
As federal agencies operate to implement the executive order, stakeholders await further guidance on safety protocols, therapist training standards, and equitable access measures. The next key checkpoint is the anticipated HHS implementation report, expected by mid-July 2025, which will detail concrete steps taken to fulfill the order’s objectives. Readers are encouraged to monitor official updates from the FDA, NIH, and White House websites for verified information on policy developments.
If you have experience with mental health treatment innovations or questions about psychedelic-assisted therapy research, we invite you to share your perspective in the comments below. Your insights facilitate foster informed discussion on this evolving topic. Please share this article with others who may benefit from understanding the current landscape of federal mental health policy.